Novo Nordisk’s stock has dramatically fallen by 58% from its high in December 2024, reducing from nearly $116 to around $48. This sharp decline highlights the extreme selling pressure the company faces, primarily marked by a persistent descending trendline impeding rally attempts.

A critical support zone at $48-49, referred to as the “Line In The Sand,” has emerged, offering potential for a reversal. This level could prove essential for investors hoping to see the stock regain stability. If Novo Nordisk maintains this support level, relief rallies might push the stock towards $52-54, although overcoming the prevailing downward trend remains challenging.

If the stock drops below the $48 mark, it may fall towards the $42-44 range. Volume will play a critical role here, distinguishing between a confirmed capitulation and a potential false break.

Novo Nordisk operates amid fluctuating sentiment due to its sector’s sensitivity to drug trial results and regulatory changes. Traders are keenly observing whether $48 will mark the stock’s floor or if further declines are imminent. Identifying the stock’s trajectory from this juncture poses classic risk-reward dynamics for market participants.

We are watching Novo Nordisk test a critical $48 support level after a brutal decline from its highs near $116 back in December 2024. Options markets are pricing in massive uncertainty, with implied volatility hitting levels not seen since the competitive data from Eli Lilly emerged in mid-2025. This tells us traders are betting on a significant price swing in the coming weeks.

For those expecting a bounce from this oversold territory, buying short-dated call options could offer significant leverage. With short interest recently reported by S&P Global at over 15% of the float, any positive news could trigger a powerful short squeeze, pushing the stock towards that initial $52 resistance. This is a high-risk play on the stock being fundamentally undervalued after the panic.

However, if we see a decisive break below $48 on heavy volume, the bearish case strengthens considerably. Considering their Q3 2025 earnings revealed the first-ever sequential decline in Wegovy prescriptions, further downside towards the $42-$44 range seems plausible. Buying put options or establishing bear call spreads would be the direct plays for such a scenario.

Given the binary nature of this setup, waiting for confirmation is a prudent approach before committing heavily. An alternative strategy is to trade the volatility itself, perhaps through a long straddle, which would profit from a large price move in either direction. This approach is designed for moments like this, where the direction is unclear but a significant move feels imminent.

We have seen similar patterns in the past, where a former market leader faces a major competitive threat and sees its valuation reset. Looking back at how stocks like Gilead Sciences behaved in the mid-2010s after their hepatitis C market dominance was challenged shows that these downtrends can be prolonged. Right now, all eyes are on that “Line In The Sand” at $48, which will dictate the next major move for Novo Nordisk.